Reviews/Ssris and Snris/Venlafaxine causes dose-dependent blood pressure elevation
· SS-SAF-04 · v2
The corpus shows fairly consistently that venlafaxine can raise blood pressure. A controlled trial in children found significant blood-pressure changes on the drug [5], and two separate poisoning series found high blood pressure in roughly a quarter to two-fifths of patients [7][8]. The harder part of the claim is the word 'dose-dependent': where the studies actually measured a dose relationship, it was for heart-rhythm measures or a bundle of cardiac events, not for blood pressure itself [6][7][8]. The clearest statements that higher doses raise blood pressure appear only in review articles the panel set aside as not primary evidence [9][16]. So the panel accepted that venlafaxine elevates blood pressure but treated the dose-dependence part as supported only indirectly.
A placebo-controlled pediatric trial reports statistically significant blood-pressure changes in the venlafaxine arm [5]. Two independent overdose series document raised blood pressure, with mild hypertension in 40% and severe in 3% of exposures [7] and high blood pressure in 28.4% [8], and a case report notes hypertension among vital-sign changes in overdose [17]. A pharmacovigilance analysis links daily venlafaxine dose to a range of cardiovascular adverse events but not to hypertension specifically [6]. Where dose relationships are actually quantified, they are for QT and heart rate [7][8], not for blood pressure. The contested point: The division is over the 'dose-dependent' qualifier rather than the blood-pressure effect itself. No eligible primary paper plots a therapeutic dose against blood pressure: the measured dose correlations are for QT and heart rate [7][8] or a cardiovascular-event composite [6], and the explicit dose-BP statements live only in study-type-excluded reviews [9][16].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Dose-dependence of BP is not directly measured in any eligible primary paper: the dose correlations in [7] and [8] are for QT and heart rate, and [6]'s dose signal is a cardiovascular-event composite, not hypertension. The 'dose-dependent' qualifier rests on inference.
The strongest BP-elevation data ([7], [8], [17]) come from overdose/poisoning cohorts; extrapolating overdose hypertension to a therapeutic dose-response relationship is an indirectness leap.
Where it remains uncertain. The dose relationships that were actually measured are for QT and heart rate [7][8] or a cardiovascular-event composite [6], not for blood pressure, and [6] reports cardiovascular-death risk did not increase with regular doses.
Aleatory
Hypertension appears in a range (28.4% in [8], 40% mild and 3% severe in [7]), reflecting patient-to-patient variability in how exposure translates to blood-pressure response.
Epistemic
No eligible primary paper measures blood pressure against therapeutic dose; the quantified dose relationships in [7] and [8] are for QT and heart rate, so the dose-BP relationship is simply not characterised.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT-level causal evidence that venlafaxine alters BP, but flexible dosing gives no dose-response and population is pediatric.
“Statistically significant changes in height, weight, blood pressure, pulse, and cholesterol levels were observed in the extended-release venlafaxine group.”
Panel auditInternal validity: medium · scope of inference: Pediatric (ages 6-17) generalized anxiety disorder, flexible-dose venlafaxine XR.Key limitations: direction of BP change unstated · flexible dose, no dose-response · pediatric population
Shows a dose-outcome relationship for cardiovascular events generally, but does not isolate hypertension/BP elevation.
“VEN daily dose was associated with increased risks of cardiac arrhythmias, embolic and thrombotic events, torsade de pointes/QT prolongation, ischaemic heart disease, cardiac failure, cardiomyopathy and overall cardiovascular events.”
Panel auditInternal validity: low · scope of inference: Reported cardiovascular adverse events among venlafaxine users, by dose.Key limitations: BP elevation not among events analysed · spontaneous-report data · no exposure denominator
Documents frequent BP elevation after venlafaxine exposure, in overdose context.
“with larger doses being more likely to be associated with an abnormal QT”
Panel auditInternal validity: medium · scope of inference: Haemodynamic and ECG effects of venlafaxine overdose (median 1500 mg) in a toxicology unit.Key limitations: overdose not therapeutic dosing · dose-response shown for QT not BP · no comparison group
Case-level note of hypertension with venlafaxine; no dose-response.
“substantial changes in vital signs (hypertension and hypotension)”
Panel auditInternal validity: low · scope of inference: Conduction disturbances in one venlafaxine overdose patient.Key limitations: single case · overdose with co-ingestants · both hyper- and hypotension noted
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The blood-pressure-elevation effect is solid but the specific dose-dependence of BP is supported only by overdose-context and composite-outcome inference, so the claim as worded warrants an Uncertain tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No therapeutic dose-blood-pressure response curve. The claim's 'dose-dependent' qualifier has no direct primary support; existing dose correlations are for QT and heart rate [7][8] or a CV composite [6]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective therapeutic-dose study stratifying patients by venlafaxine dose with ambulatory blood-pressure measurement as the pre-specified dose-linked outcome.
Open question: Does venlafaxine blood-pressure elevation increase monotonically with therapeutic dose? Why it is still open: The only quantified dose relationships in the corpus are for QT and heart rate [7][8] and a cardiovascular-event composite [6], never blood pressure.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19